A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

This trial is testing an experimental cell therapy called LCAR-HL30 — a type of CAR-T therapy targeting a protein called CD30 — in people with Hodgkin's lymphoma or a related blood cancer called anaplastic large cell lymphoma (ALCL) that has relapsed or stopped responding to treatment. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with Hodgkin's lymphoma or anaplastic large cell lymphoma that is CD30-positive - Your cancer has come back or is no longer responding to prior treatments - You are in reasonably good physical condition (ECOG 0–1 in dose escalation; up to 2 in expansion) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have active brain involvement of your lymphoma - You have had a prior allogeneic stem cell transplant - You have serious organ dysfunction, active infection, or autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.